In This Article:
The ASX200 closed up 0.58% at 8,091.9 points, with the last day of the earnings season bringing mixed results across various sectors, while retail sales data from July showed a plateau in activity. As analysts digest these developments and consider their implications for interest rates, it is crucial to identify high-growth tech stocks that exhibit strong fundamentals and resilience in a fluctuating market environment like Australia's.
Top 10 High Growth Tech Companies In Australia
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Infomedia | 7.59% | 21.65% | ★★★★★☆ |
| Clinuvel Pharmaceuticals | 22.41% | 27.42% | ★★★★★★ |
| AVA Risk Group | 32.46% | 118.83% | ★★★★★★ |
| DUG Technology | 10.90% | 32.21% | ★★★★★☆ |
| Xero | 13.50% | 24.14% | ★★★★★☆ |
| Wrkr | 32.87% | 124.86% | ★★★★★★ |
| Careteq | 24.12% | 104.18% | ★★★★★☆ |
| Adveritas | 50.14% | 144.21% | ★★★★★★ |
| SiteMinder | 19.40% | 60.46% | ★★★★★☆ |
| Senetas | 14.33% | 118.52% | ★★★★★☆ |
Click here to see the full list of 57 stocks from our ASX High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Opthea
Simply Wall St Growth Rating: ★★★★★☆
Overview: Opthea Limited is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for eye diseases in Australia, with a market cap of A$720.19 million.
Operations: Opthea Limited is focused on developing and commercializing therapies for eye diseases in Australia. As a clinical stage biopharmaceutical company, it currently does not generate revenue.
Opthea's revenue is projected to grow at an impressive 53.7% annually, significantly outpacing the Australian market's 5.3% growth rate. Despite a net loss of $220.24 million for the year ending June 30, 2024, the company is expected to achieve profitability within three years, with earnings forecasted to increase by 57.86% per year. The recent formation of a Medical Advisory Board aims to enhance its clinical programs and address unmet medical needs in retinal diseases, positioning Opthea for future advancements in ophthalmology.
-
Delve into the full analysis health report here for a deeper understanding of Opthea.
-
Gain insights into Opthea's historical performance by reviewing our past performance report.
REA Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: REA Group Limited, along with its subsidiaries, operates an online property advertising business across Australia, India, the United States, Malaysia, Singapore, Thailand, Vietnam, and other international markets with a market cap of A$28.91 billion.
Operations: REA Group generates revenue primarily from online property advertising, with significant contributions from its Australian Property & Online Advertising segment (A$1.25 billion) and Financial Services segment (A$320.60 million), as well as its operations in India (A$103.10 million). The company focuses on digital real estate services across various international markets, leveraging its extensive online platforms to connect buyers, sellers, and renters.